Motomi Osato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Motomi Osato has a total of 760 co-authors. Here are the top co-authors by number of shared publications:
- Wee Joo Chng
Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
42 shared publications - Ahmed M. Mamdouh
Department of Pharmacy, National University of Singapore, Singapore
35 shared publications - Anthony Letai
Dana-Farber Cancer Institute, Boston, USA
35 shared publications - Binyam Yilma
Tempus AI, Inc, Chicago, IL
35 shared publications - Chuqi Wang
Department of Pharmacy & Pharmaceutical Sciences, National University of Singapore, Singapore 117559, Singapore
35 shared publications - David M. Weinstock
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
35 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Telomere variant sequences encode the genetic blueprint for allele-specific telomere length
The ends of human chromosomes are capped by specialized nucleoprotein structures, termed telomeres, which are essential for genome stability. Recent advances in long-read sequencing have enabled allele-specific telomere length measurements at nucleotide resolution, uncovering extreme heterogeneity in telomere length between alleles. The progressive telomere shortening over time makes steady-state telomere length in human somatic cells a promising biomarker for age-associated diseases. However, the mechanisms underlying allele-specific telomere maintenance and its stability remain poorly understood. Here, we developed a high-resolution workflow combining PacBio and Nanopore long-read sequencing platforms to map allele-specific telomere length in human blood samples as well as cultured cell lines. By tracing allele-specific telomeric sequence in family members across multiple generations, we show that the allele-specific telomeric variant sequences (TVSs) are heritable and underlie the extreme heterogeneity of telomere length between alleles. Continuous cell proliferation likely drives the slow but stochastic evolution of allele-specific TVSs, resulting in asymmetry in telomere inheritance from father and mother (p-value = 2.354e-7). Targeted deletion of allele-specific TVSs using CRISPR-Cas9 resets telomere length, further confirming their causal role in the control of allele-specific telomere maintenance. These results indicated that TVSs are heritable genetic elements underlying the allele-specific telomere length.
- 7 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTelomere variant sequences encode the genetic blueprint for allele-specific telomere length
The ends of human chromosomes are capped by specialized nucleoprotein structures, termed telomeres, which are essential for genome stability. Recent advances in long-read sequencing have enabled allele-specific telomere length measurements at nucleotide resolution, uncovering extreme heterogeneity in telomere length between alleles. The progressive telomere shortening over time makes steady-state telomere length in human somatic cells a promising biomarker for age-associated diseases. However, the mechanisms underlying allele-specific telomere maintenance and its stability remain poorly understood. Here, we developed a high-resolution workflow combining PacBio and Nanopore long-read sequencing platforms to map allele-specific telomere length in human blood samples as well as cultured cell lines. By tracing allele-specific telomeric sequence in family members across multiple generations, we show that the allele-specific telomeric variant sequences (TVSs) are heritable and underlie the extreme heterogeneity of telomere length between alleles. Continuous cell proliferation likely drives the slow but stochastic evolution of allele-specific TVSs, resulting in asymmetry in telomere inheritance from father and mother (p-value = 2.354e-7). Targeted deletion of allele-specific TVSs using CRISPR-Cas9 resets telomere length, further confirming their causal role in the control of allele-specific telomere maintenance. These results indicated that TVSs are heritable genetic elements underlying the allele-specific telomere length.
- Open Access
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eaeb4830
Threat assessment shapes neutrophil cell fate upon inflammasome activation
Inflammasomes are cytosolic multiprotein complexes that activate caspase-1, which promotes inflammation and host defense by driving cytokine maturation and pyroptosis. Several studies reported that caspase-1 selectively drives cytokine maturation without concomitant pyroptosis in neutrophils, yet the molecular mechanisms by which neutrophils resist caspase-1–dependent pyroptosis remain unclear. Here, we report that granulocyte-macrophage colony-stimulating factor (GM-CSF) licenses neutrophil pyroptosis upon NLRP3 and Pyrin activation by amplifying TLR4-driven inflammasome priming. Single priming with the TLR1/2 agonist, Pam3CSK4, was also sufficient to license neutrophils to pyroptosis upon NLRP3 and Pyrin activation, as Pam3CSK4 triggered superior inflammasome priming compared to LPS, the prototypic inflammasome priming agent. We further demonstrate that neutrophil pyroptosis requires autocrine TNFR1 signaling and provides genetic evidence that Ninj1 K45Q/K45Q mutation disrupts plasma membrane rupture in pyroptotic neutrophils. In contrast, NLRC4 expression was not further induced by GM-CSF and therefore does not enhance susceptibility to NLRC4-dependent pyroptosis. Collectively, our data demonstrate that the inflammatory environment dictates neutrophil cell fate upon inflammasome activation.
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eaeb4830
Open AccessThreat assessment shapes neutrophil cell fate upon inflammasome activation
Inflammasomes are cytosolic multiprotein complexes that activate caspase-1, which promotes inflammation and host defense by driving cytokine maturation and pyroptosis. Several studies reported that caspase-1 selectively drives cytokine maturation without concomitant pyroptosis in neutrophils, yet the molecular mechanisms by which neutrophils resist caspase-1–dependent pyroptosis remain unclear. Here, we report that granulocyte-macrophage colony-stimulating factor (GM-CSF) licenses neutrophil pyroptosis upon NLRP3 and Pyrin activation by amplifying TLR4-driven inflammasome priming. Single priming with the TLR1/2 agonist, Pam3CSK4, was also sufficient to license neutrophils to pyroptosis upon NLRP3 and Pyrin activation, as Pam3CSK4 triggered superior inflammasome priming compared to LPS, the prototypic inflammasome priming agent. We further demonstrate that neutrophil pyroptosis requires autocrine TNFR1 signaling and provides genetic evidence that Ninj1 K45Q/K45Q mutation disrupts plasma membrane rupture in pyroptotic neutrophils. In contrast, NLRC4 expression was not further induced by GM-CSF and therefore does not enhance susceptibility to NLRC4-dependent pyroptosis. Collectively, our data demonstrate that the inflammatory environment dictates neutrophil cell fate upon inflammasome activation.
- Open Access
RUNX1-ETO expression in epidermal keratinocytes induces progressive skin inflammation in vivo
Basal keratinocytes in the skin are essential for epidermal homeostasis and repair; however, how intrinsic alterations in these cells contribute to inflammatory skin pathology remains poorly understood. In this study, we employed a tamoxifen-inducible mouse model to express the human RUNX1-ETO fusion gene, a well-established oncogenic driver of acute myeloid leukemia, in epidermal basal keratinocytes. RUNX1-ETO induction in keratinocytes resulted in progressive skin inflammation in vivo, accompanied by splenomegaly, epidermal hyperplasia, increased cytokine production, and alterations in epidermal stem cell composition. Inflammatory lesions were prominent in the tail, ear, and plantar epidermis, whereas hair-bearing dorsal skin remained largely unaffected. RNA-seq analysis of FACS-isolated RUNX1-ETO+ basal keratinocytes revealed global changes in gene expression, characterized by the suppression of epidermal homeostatic and metabolic programs and the activation of inflammatory signaling pathways. In particular, RUNX1-ETO expression was associated with increased TNF/NF-kB and IL-6-STAT signaling, as well as interferon-associated inflammatory pathways, together with the induction of neutrophil-attracting chemokines and epithelial inflammatory mediators. Together, these findings indicate that RUNX1-ETO-mediated transcriptional dysregulation in basal keratinocytes promotes a pro-inflammatory cellular state that drives progressive skin inflammation.
Open AccessRUNX1-ETO expression in epidermal keratinocytes induces progressive skin inflammation in vivo
Basal keratinocytes in the skin are essential for epidermal homeostasis and repair; however, how intrinsic alterations in these cells contribute to inflammatory skin pathology remains poorly understood. In this study, we employed a tamoxifen-inducible mouse model to express the human RUNX1-ETO fusion gene, a well-established oncogenic driver of acute myeloid leukemia, in epidermal basal keratinocytes. RUNX1-ETO induction in keratinocytes resulted in progressive skin inflammation in vivo, accompanied by splenomegaly, epidermal hyperplasia, increased cytokine production, and alterations in epidermal stem cell composition. Inflammatory lesions were prominent in the tail, ear, and plantar epidermis, whereas hair-bearing dorsal skin remained largely unaffected. RNA-seq analysis of FACS-isolated RUNX1-ETO+ basal keratinocytes revealed global changes in gene expression, characterized by the suppression of epidermal homeostatic and metabolic programs and the activation of inflammatory signaling pathways. In particular, RUNX1-ETO expression was associated with increased TNF/NF-kB and IL-6-STAT signaling, as well as interferon-associated inflammatory pathways, together with the induction of neutrophil-attracting chemokines and epithelial inflammatory mediators. Together, these findings indicate that RUNX1-ETO-mediated transcriptional dysregulation in basal keratinocytes promotes a pro-inflammatory cellular state that drives progressive skin inflammation.
- 19 October 2025
- Published by Wiley in Genes to Cells
- Vol. 30 (6) , e70052
An Upstream RUNX3 Enhancer, eR3 (−18m/−28h), Regulates the Development of Gut‐Associated Anti‐Tumorigenic CD8 + CD103 + Cytotoxic T Lymphocytes in Mouse and Human
The RUNX3 gene is frequently involved in a variety of cancers and immunological diseases. Despite such widespread association with human diseases, the transcriptional regulation of RUNX3 remains elusive. Here we report the identification of an enhancer for Runx3 , eR3(−18m/−28h) , by employing a combination of in silico prediction and in vivo verification using zebrafish and mouse models. eR3 is active in CD8 + CD103 (integrin α E ) + cytotoxic T lymphocytes (CTLs) that reside in the intestinal epithelium via their interaction with the CD103 ligand, E‐cadherin, on epithelial cells. Removal of eR3(−18m) specifically in CD8 T cells compromised the suppression of tumorigenesis in murine cancer models. In humans, single nucleotide polymorphisms (SNPs) in eR3(−28h) were overrepresented and were associated with weakened CTL activity in colorectal cancer patients. Together, our results indicate that eR3 plays a role in immune surveillance against gut‐associated tumors by upregulating RUNX3 expression in specific CTLs.
- 19 October 2025
- Published by Wiley in Genes to Cells
- Vol. 30 (6) , e70052
An Upstream RUNX3 Enhancer, eR3 (−18m/−28h), Regulates the Development of Gut‐Associated Anti‐Tumorigenic CD8 + CD103 + Cytotoxic T Lymphocytes in Mouse and Human
The RUNX3 gene is frequently involved in a variety of cancers and immunological diseases. Despite such widespread association with human diseases, the transcriptional regulation of RUNX3 remains elusive. Here we report the identification of an enhancer for Runx3 , eR3(−18m/−28h) , by employing a combination of in silico prediction and in vivo verification using zebrafish and mouse models. eR3 is active in CD8 + CD103 (integrin α E ) + cytotoxic T lymphocytes (CTLs) that reside in the intestinal epithelium via their interaction with the CD103 ligand, E‐cadherin, on epithelial cells. Removal of eR3(−18m) specifically in CD8 T cells compromised the suppression of tumorigenesis in murine cancer models. In humans, single nucleotide polymorphisms (SNPs) in eR3(−28h) were overrepresented and were associated with weakened CTL activity in colorectal cancer patients. Together, our results indicate that eR3 plays a role in immune surveillance against gut‐associated tumors by upregulating RUNX3 expression in specific CTLs.
- 13 June 2024
- Published by Elsevier in Experimental Hematology
- Vol. 137, 104255
Activation of NOTCH signaling impedes cell proliferation and survival in acute megakaryoblastic leukemia
- 13 June 2024
- Published by Elsevier in Experimental Hematology
- Vol. 137, 104255
Activation of NOTCH signaling impedes cell proliferation and survival in acute megakaryoblastic leukemia
- Open Access
- 22 May 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 722, 150155
Expression pattern of Runt-related transcription factor (RUNX) family members and the role of RUNX1 during kidney development
- 22 May 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 722, 150155
Open AccessExpression pattern of Runt-related transcription factor (RUNX) family members and the role of RUNX1 during kidney development
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 2 shows sample IDs submitted for RNA-seq.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 2 shows sample IDs submitted for RNA-seq.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S12 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 12 shows targeted agents cluster by mechanism of action.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 12 shows targeted agents cluster by mechanism of action.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 4 shows raw baseline BH3 profiling data on matched pre- and post-resistant AML PDX models.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 4 shows raw baseline BH3 profiling data on matched pre- and post-resistant AML PDX models.